CMC Biologics Honored as Finalist for Washington's Manufacturing Company of the Year Award

SEATTLE, May 3, 2012 /PRNewswire/ -- CMC Biologics, a leading contract manufacturing organization (CMO) known and respected for its technical excellence in process development and cGMP manufacture, has been named a finalist for  the 2012 Manufacturing Company of the Year – Large Category.   The Seattle Business Magazine's Washington Manufacturing Awards, in partnership with Impact Washington, brought together nearly 300 leaders in manufacturing from around the state.

(Logo: http://photos.prnewswire.com/prnh/20110502/SF93356LOGO )

"CMC Biologics has been operating in Washington state as a thriving biopharmaceutical contract manufacturer since 2007.  With nearly 450 talented and hardworking employee's world-wide, we continue to grow and to hire locally and globally at our manufacturing facility in Bothell, as well as our facility in Copenhagen, Denmark," said Gustavo Mahler, Chief Operations Officer for the company. "We are positioned to be the leader among CMO's in customer satisfaction and technical excellence, and are excited to be considered a top manufacturer among dozens of companies in this competition."

"The life sciences industry is one of the fastest growing economic drivers of our state, and companies like CMC Biologics as a biopharmaceutical manufacturer, are providing the people of Washington with good jobs and a prosperous future," stated Gubernatorial Candidate Jay Inslee.  "I'd like to congratulate the team at CMC Biologics for their hard work and dedication as a finalist for Washington's Manufacturer of the Year."

As the state's largest biopharmaceutical manufacturer, CMC Biologics' contribution to the economy is significant.  In 2011, CMC Biologics completed the expansion of a state-of the art stainless steel biopharmaceutical manufacturing facility, utilizing local contractors and suppliers.  This expansion added significant production capacity to accommodate growing demand for cGMP commercial manufacture of biopharmaceuticals and to support commercial manufacturing and was the second stage of a major manufacturing expansion plan that started with the construction of a multi‑purpose single-use facility completed in 2010.

About CMC Biologics

CMC Biologics is a leading contract development and manufacturing organization that provides fully integrated biopharmaceutical development and manufacturing solutions to clients around the world, from its facilities in Europe and the USA.  The company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and in-market production.  The company's wide range of integrated services includes cell line development, bioprocess development, formulation and comprehensive analytical testing.  Clients can also benefit from CMC Biologics' proprietary CHEF1® expression system for mammalian production.  CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes.  CMC Biologics is located in Copenhagen, Denmark, and Seattle, Washington. Visit www.cmcbio.com  to learn more.

SOURCE CMC Biologics

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED